Management of patients with depression associated with anxiety symptoms

Journal of Clinical Psychiatry

Volumn 58, Issue SUPPL. 8, 1997, Pages 11-16

  Nutt, David ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMITRIPTYLINE; BENZODIAZEPINE DERIVATIVE; CLOMIPRAMINE; DESIPRAMINE; DIAZEPAM; FLUOXETINE; FLUVOXAMINE MALEATE; IMIPRAMINE; LORAZEPAM; MAPROTILINE; MIANSERIN; MIDAZOLAM; PAROXETINE; PRAZEPAM; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; ZELMED; ZIMELDINE;

ANXIETY; CLINICAL PRACTICE; CONFERENCE PAPER; DEPRESSION; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; PREVALENCE; PRIORITY JOURNAL;

ANTIDEPRESSIVE AGENTS, TRICYCLIC; ANXIETY DISORDERS; BENZODIAZEPINES; COMORBIDITY; DEPRESSIVE DISORDER; DRUG THERAPY, COMBINATION; HUMANS; PREVALENCE; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 0030738462     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (67)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised. Washington, DC: American Psychiatric Association; 1987:124-125
2. Stahl SM. Mixed anxiety and depression: clinical implications. J Clin Psychiatry 1993;54(suppl 1):33-38
3. ICD-10. Classification of Mental and Behavioral Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva, Switzerland: World Health Organization; 1992
4. Coryell W, Endicott J, Andreasen N, et al. Depression and panic attacks: the significance of overlap as reflected in follow-up and family study data. Am J Psychiatry 1988;145:293-300
5. Wittchen H-U, Essau CA. Comorbidity and mixed anxiety-depressive disorders: is there epidemiologic evidence? J Clin Psychiatry 1993;54(suppl 1):9-15
6. Angst J, Dobler-Mikola A. A continuum from depression to anxiety disorders? Eur Arch Psychiatry Clin Neurosci 1985;235:179-186
7. Regier DA, Boyd JH, Burke JD, et al. One-month prevalence of mental disorders in the US: based on five Epidemiologic Catchment Area sites. Arch Gen Psychiatry 1988;45:977-986
8. Hamilton M. Distinguishing between anxiety and depressive disorders. In: Last CA, Hersen M, eds. Handbook of Anxiety Disorders. New York, NY: Pergamon Press; 1988:143-155
9. Roth M, Gurney C, Garside RF, et al. Studies in the classification of affective disorders: the relationship between anxiety states and depressive illness. Br J Psychiatry 1972;121:147-161
10. Fawcett J, Kravitz HM. Anxiety syndromes and their relationship to depressive illness. J Clin Psychiatry 1983;44:8-11
11. Lydiard RB. Coexisting depression and anxiety: special diagnostic and treatment issues. J Clin Psychiatry 1991;52(suppl 6):48-54
12. Judd L. Comorbidity and health costs. International Med News 1994; 92(2):4-5
13. Clayton PJ, Grove WM, Coryell W, et al. Follow-up and family study of anxious depression. Am J Psychol 1991;148:1512-1517
14. Liebowitz MR. Depression with anxiety and atypical depression. J Clin Psychiatry 1993;54(suppl 2):10-14
15. Goldberg D, Huxley P. Common Mental Disorders. London, England: Routledge; 1992
16. Kamerow DB. Anxiety and depression in the medical setting: an overview. Med Clin North Am 1988;72(4):745-751
17. Clayton PJ. Comorbidity factor: establishing the primary diagnosis in patients with mixed symptoms of anxiety and depression. J Clin Psychiatry 1990;51(suppl 11):35-39
18. Fawcett J, Scheftner WA, Fogg L, et al. Time-related predictors of suicide in major affective disorder. Am J Psychiatry 1990;147:1189-1194
19. Murphy J, Oliver DC, Sobol AM, et al. Diagnosis and outcome: depression and anxiety in a general population. Psychol Med 1986;16:117-126
20. Noyes RJ, Clancy J, Hoenk PR, et al. The prognosis of anxiety neurosis. Arch Gen Psychiatry 1980;37:173-178
21. Johnson J, Weissman MM, Kierman GL. Panic disorder, comorbidity and suicide attempts. Arch Gen Psychiatry 1990;47:805-808
22. Young LT, Cooke RG, Robb JC, et al. Anxious and non-anxious bipolar disorder. J Affect Disord 1993;29:49-52
23. Fawcett J. Targeting treatment in patients with mixed symptoms of anxiety and depression. J Clin Psychiatry 1990;51(suppl 11):40-43
24. Regier DA, Narrow WE, Rae DS, et al. Epidemiological Catchment Area prospective one-year prevalence rates of disorders and services. Arch Gen Psychiatry 1993;50:85-94
25. Fawcett J. The detection and consequences of anxiety in clinical depression. J Clin Psychiatry 1997;58(suppl 8):35-40
26. Rickels K, Schweizer E. The treatment of generalized anxiety disorder in patients with depressive symptomatology. J Clin Psychiatry 1993;54(suppl 1):20-23
27. Kasper S. Pharmacological treatment of mixed anxiety and depression [abstract]. Proceedings of the VII Congress of the European College of Neuropsychopharmacology; Oct 16-21, 1994; Jerusalem, Israel
28. Hoehn-Saric R, McLeod DR, Zimmerli WD. Differential effects of alprazolam and imipramine in generalized anxiety disorder: somatic versus psychic symptoms. J Clin Psychiatry 1988;49:293-301
29. Rickels K, Downing R, Schweizer E. Antidepressants for the treatment of generalized anxiety: a placebo-controlled comparison of imipramine, trazodone, and diazepam. Arch Gen Psychiatry 1993;50:884-895
30. Johnstone EC, Owens DGC, Frith CD, et al. Neurotic illness and its response to anxiolytic and antidepressant treatment. Psychol Med 1980;10: 321-328
31. Eison MS. Serotonin: a common neurobiologic substrate in anxiety and depression. J Clin Psychopharmacol 1990;10:26S-30S
32. Baldwin D, Rudge S. The role of serotonin in depression and anxiety. Int Clin Psychopharmacol 1995;9(suppl 4):41-45
33. Anderson IM, Tomenson BM. The efficacy of selective serotonin re-uptake inhibitors in depression: a meta analysis of studies against tricyclic antidepressants. J Clin Psychopharmacol 1994;8:238-249
34. Feighner JP, Boyer WF. Paroxetine in the treatment of major depression. Acta Psychiatr Scand 1989;80:125-129
35. Feighner JP, Boyer WF, Meredith CH, et al. A placebo-controlled inpatient comparison of fluvoxamine maleate and imipramine in major depression. Int Clin Psychopharmacol 1989;4:239-244
36. Kasper S, Fuger J, Moller HJ. Comparative efficacy of antidepressant. Drugs 1992;43(suppl 2):11-23
37. Den Boer JA, Westenberg HGM, Kamerbeek WDJ, et al. Effect of serotonin uptake inhibitors in anxiety disorders: a double blind comparison of clomipramine and fluvoxamine. Int Clin Psychopharmacol 1987;2:21-32
38. Kasper S. Neurobiology and new psychopharmacological strategies for treatment of anxiety disorders. In: Racagni, Brunelli, eds. Current Therapeutical Approaches on Panic and Other Anxiety Disorders. Basel, Switzerland: Karger; 1995
39. Laws D, Ashford JJ, Anstee JA. A multicentre double-blind comparative trial of fluvoxamine versus lorazepam in mixed anxiety and depression treated in general practice. Acta Psychiatr Scand 1990;81:185-189
40. Chabannes J-P, Séchier P, Baro P. Traitement des états anxiodépressifs. Étude comparative en double insu de la fluvoxamine versus diazépam. Nervure 1989;7(suppl):1-4
41. Chabannes JP, Douge R, Baro P, et al. Fluvoxamine and anxiety: efficacy of fluvoxamine on anxiety in two double blind comparative studies among anxio-depressed patients. Presented at the VIII World Congress of Psychiatry; October 1989; Athens, Greece
42. Kasper S, Möller H-J, Montgomery SA, et al. Antidepressant efficacy in relation to item analysis and severity of depression: a placebo-controlled trial of fluvoxamine versus imipramine. Int Clin Psychopharmacol 1995;9 (suppl 4):3-12
43. Feighner JP, Boyer WF. Paroxetine in the treatment of depression: a comparison with imipramine and placebo. J Clin Psychiatry 1992;53(suppl 2):44-47
44. Dunner DL, Dunbar GC. Managing the patient with depression and anxiety. European Psychiatry 1993;8(suppl 1):9-12
45. Beasley CM, Sayler ME, Bosomworth JC, et al. High-dose fluoxetine: efficacy and activating-sedating effects in agitated and retarded depression. J Clin Psychopharmacol 1991;11:166-174
46. Nutt D. The anxiety factor in depression. J Clin Psychopharmacol 1995;9 (suppl):185-189
47. Montgomery SA, Kasper S. Comparison of compliance between serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. Int Clin Psychopharmacol 1995;9(suppl 4):33-40
48. Sussman N, Chou JCY. Current issues in benzodiazepine use for anxiety disorders. Psychiatr Ann 1988;18:139-145
49. Cross-National Collaborative Panic Study, Second Phase Investigators. Drug treatment of panic disorder: comparative efficacy of alprazolam, imipramine, and placebo. Br J Psychiatry 1992;160:191-202
50. Nutt DJ, Bell CJ, Potokar JP. Drug treatment of chronic anxiety. In: Ancill RJ, Lader MH, eds. Pharmacologic Management of Chronic Psychiatric Disorders. London: Balliere Tindall; 1995
51. Cook MD, Conner J. Retrospective review of hypnotic use in combination with fluoxetine or sertraline. Clinical Drug Investigation 1995;9:212-216
52. Patat A, Klein MJ, Hucher M, et al. Acute effects of amitriptyline on human performance and interactions with diazepam. Eur J Clin Pharmacol 1988; 35:585-592
53. Grasela TH Jr, Ereshefsky L, Wells BG, et al. An evaluation of population pharmacokinetics in therapeutic trials, part II: detection of a drug-drug interaction. Clin Pharmacol Ther 1987;42:433-441
54. De Jonghe F, Swinkels JA. The safety of antidepressants. Drugs 1992;43 (suppl 2):40-47
55. Gorman JM, Liebowitz MR, Fyer AJ, et al. An open trial of fluoxetine in the treatment of panic attacks. J Clin Psychopharmacol 1987;7:329-332
56. Benfield P, Heel RC, Lewis SP. Fluoxetine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 1986;32:481-508
57. Huitfeldt B, Montgomery SA. Comparison between zimelidine and amitriptyline of efficacy and adverse symptoms. Acta Psychiatr Scand 1983;69 (suppl 308):55-69
58. Sommi RW, Crismon ML, Bowden CL. Fluoxetine: a serotonin-specific, second-generation antidepressant. Pharmacotherapy 1987;7:1-15
59. Stokes PE. Fluoxetine: a five-year review. Clin Ther 1993;15:216-243
60. Wagner W, Zaborny BA, Gray TE. Fluvoxamine: a review of its safety profile in world-wide studies. Int Clin Psychopharmacol 1994;9:223-227
61. Fox T. Drug treatment of anxiety and depression. Practitioner 1990;233: 681-683
62. Leonard BE. Pharmacological differences of serotonin reuptake inhibitors and possible clinical relevance. Drugs 1992;43:3-9
63. Rudorfer MV, Manji HK, Potter WZ. Comparative tolerability profiles of the newer versus older antidepressants. Drug Saf 1994;10:18-46
64. Swinkels JA, de Jonghe F. Safety of antidepressants. Int Clin Psychopharmacol 1995;9(suppl 4):19-25
65. Hindmarch I. The behavioral toxicity of the selective serotonin reuptake inhibitors. Int Clin Psychopharmacol 1995;9(suppl 4):13-17
66. Ray WA, Fought RL, Decker MD. Psychoactive drugs and the risk of injurious motor vehicle crashes in elderly drivers. Am J Epidemiol 1992; 136:873-883
67. Wagner W, Zaborhni BA, Grey G, et al. Fluvoxamine: a review of its safety profile in worldwide studies. Int Clin Psychopharmacol 1994;9:223-227